Homepage Top Section2

This allosteric pan-mutant-selective phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor and degrader is poised to enter first-in-human trials in the second quarter of this year. According to the company, mutant

Effexor, a serotonin-noradrenaline reuptake inhibitor (SNRI), has shown promise in treating GAD in adults through a recent study in Japan. The Phase III trial, Study B2411367, confirmed venlafaxine’s

This clearance is intended for treating solid tumours in adults, with a focus on head & neck cancer, breast cancer and soft tissue sarcoma. Preclinical data included in

The funding round was spearheaded by CTI Life Sciences Fund, Advent Life Sciences, and abrdn-managed funds. Current investors, including Sanofi Ventures, Novo Holdings, RiverVest Venture Partners, Sanderling Ventures,

This transaction is said to be contingent on receiving customary regulatory approvals. Theravia’s portfolio includes Siklos for sickle cell disease and Orphacol for genetic disorders affecting the liver’s

This collaboration primarily aims to concentrate on expediting production of the recessive dystrophic epidermolysis bullosa (RDEB) therapy CORDStrom. An independent technology and innovation organisation, CGT Catapult focuses on

The partnership will leverage Nona’s two heavy and two light chain (H2L2) Harbour Mice platforms to detect next-generation therapeutic candidates. The platform employs transgenic mice to produce fully

Spearheaded by Deep Track Capital, this funding round saw participation from new investors, including Catalio Capital Management, Cytokinetics, and AN Ventures, alongside contributions from current backers SV Health

This follows the company’s February announcement of a definitive merger agreement signed with BioSymetrics. This merger aims to bolster Renovaro’s data analysis and biomarker discovery capabilities, while also